These unique capabilities of PET/CT imaging may indeed be helpful in the management of RA. However, several points should be considered: first, the final goal of PET/CT imaging used in RA is to find the optimal timing of therapy (DMARDs or biologics therapy, such as anti-TNF therapy), aiming for complete remission of RA. Therefore, a multicenter prospective study involving therapeutic intervention should be conducted in the future.[29, 30] Second, PET/CT imaging used in RA can do whole-body scans to see all involved areas, but has poor specificity and is expensive. ABT-199 solubility dmso Third, limited evidence has suggested that 124I-rituximab PET/CT can detect inflamed joints in RA, with

a seemingly reasonable sensitivity, but further research is required to determine the diagnostic accuracy of this procedure, and to establish the clinical value of the findings.[15, 51]

None. None to declare. “
“To study the clinical and immunological features of primary antiphospholipid syndrome (APS), and to analyze the differences between primary VX-809 clinical trial APS and APS associated with autoimmune rheumatic disease (ARD/APS). This prospective, longitudinal study, carried out from December 2004 to July 2011 included 179 patients with primary APS and 52 patients of ARD/APS diagnosed as per modified 2006 Sapporo’s Criteria. Out of 179 patients of primary APS, 12 were male and 167 were female. The mean age at the time of study entry was 27 ± 4.33 years. Venous thrombosis was noted

in 33 (18.43%) patients. Seventeen patients had deep vein thrombosis and 11 (7.19%) had cortical vein and/or cortical sinus thrombosis. Arterial thrombosis was noted in 19 (10.61%) patients, out of which nine had intracranial arterial thrombosis. Thirty-two (17.85%) had recurrent early fetal losses (< 10 weeks) and 97 (54.18%) had late fetal loss (> 10 weeks). Immunoglobulin G (IgG) and IgM aCLA were present in 141 (78.77%) and 32 (17.87%) patients respectively, whereas lupus anticoagulant was present in 99 (55.3%) patients. In patients with bad obstetric outcome, lupus anticoagulant positivity was significantly more prevalent (P < 0.05) than aCLA positivity. Both venous and Phosphatidylinositol diacylglycerol-lyase arterial thrombosis were significantly more common (P < 0.05) in ARD/APS. However, late fetal loss was significantly more prevalent (P < 0.001) in primary APS. Primary APS may lead to a variety of clinical manifestations due to venous and/or arterial thrombosis, which at times may be lethal. It is also an important cause of early and late pregnancy loss(es) and other pregnancy morbidities. "
“Cyclo-oxygenase (COX)-2 inhibitors have been the target of severe criticism, more so following the withdrawal of Rofecoxib. Post-marketing surveillance of Celecoxib in Asian Indians, who are predisposed to premature athero-thrombotic events, has not been studied.